CN115461100A - 流体处理方法及循环处理设备、系统 - Google Patents
流体处理方法及循环处理设备、系统 Download PDFInfo
- Publication number
- CN115461100A CN115461100A CN202080100237.0A CN202080100237A CN115461100A CN 115461100 A CN115461100 A CN 115461100A CN 202080100237 A CN202080100237 A CN 202080100237A CN 115461100 A CN115461100 A CN 115461100A
- Authority
- CN
- China
- Prior art keywords
- fluid
- module
- treatment
- circulation
- pipeline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 989
- 230000004087 circulation Effects 0.000 title claims abstract description 559
- 238000011282 treatment Methods 0.000 title claims abstract description 505
- 238000000034 method Methods 0.000 title claims abstract description 228
- 230000008569 process Effects 0.000 claims abstract description 82
- 238000000926 separation method Methods 0.000 claims description 429
- 230000003197 catalytic effect Effects 0.000 claims description 424
- 239000012528 membrane Substances 0.000 claims description 269
- 239000013076 target substance Substances 0.000 claims description 161
- 230000002503 metabolic effect Effects 0.000 claims description 156
- 238000012545 processing Methods 0.000 claims description 152
- 102000004190 Enzymes Human genes 0.000 claims description 138
- 108090000790 Enzymes Proteins 0.000 claims description 138
- 230000000694 effects Effects 0.000 claims description 94
- 239000007788 liquid Substances 0.000 claims description 81
- 210000002381 plasma Anatomy 0.000 claims description 81
- 238000004064 recycling Methods 0.000 claims description 77
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- 239000000047 product Substances 0.000 claims description 63
- 238000001514 detection method Methods 0.000 claims description 60
- 238000003860 storage Methods 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 58
- 238000001914 filtration Methods 0.000 claims description 54
- 239000011148 porous material Substances 0.000 claims description 52
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 43
- 230000014759 maintenance of location Effects 0.000 claims description 41
- 230000001276 controlling effect Effects 0.000 claims description 39
- 125000004122 cyclic group Chemical group 0.000 claims description 39
- 230000008859 change Effects 0.000 claims description 38
- 210000001124 body fluid Anatomy 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 29
- 239000010839 body fluid Substances 0.000 claims description 29
- 239000000758 substrate Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 238000001179 sorption measurement Methods 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 23
- 230000009471 action Effects 0.000 claims description 22
- 239000003054 catalyst Substances 0.000 claims description 22
- 239000004005 microsphere Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 230000001105 regulatory effect Effects 0.000 claims description 19
- 241000894007 species Species 0.000 claims description 18
- 238000009295 crossflow filtration Methods 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 17
- 238000003672 processing method Methods 0.000 claims description 17
- 238000006555 catalytic reaction Methods 0.000 claims description 16
- 238000001223 reverse osmosis Methods 0.000 claims description 16
- 238000001728 nano-filtration Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012510 hollow fiber Substances 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- 230000002210 biocatalytic effect Effects 0.000 claims description 12
- 238000001471 micro-filtration Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 238000000429 assembly Methods 0.000 claims description 9
- 230000000712 assembly Effects 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 9
- 230000001502 supplementing effect Effects 0.000 claims description 9
- 201000005569 Gout Diseases 0.000 claims description 8
- 201000011252 Phenylketonuria Diseases 0.000 claims description 8
- 230000010100 anticoagulation Effects 0.000 claims description 8
- 230000008030 elimination Effects 0.000 claims description 8
- 238000003379 elimination reaction Methods 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000003094 microcapsule Substances 0.000 claims description 8
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims description 7
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 7
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 7
- 206010033645 Pancreatitis Diseases 0.000 claims description 7
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 7
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims description 7
- 201000003229 acute pancreatitis Diseases 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 7
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims description 7
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 238000011176 pooling Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 6
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 6
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 201000001431 Hyperuricemia Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 231100000836 acute liver failure Toxicity 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 239000010842 industrial wastewater Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 239000012531 culture fluid Substances 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
- 206010023388 Ketonuria Diseases 0.000 claims description 4
- 208000007976 Ketosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 238000012993 chemical processing Methods 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000013067 intermediate product Substances 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000012930 cell culture fluid Substances 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 235000021056 liquid food Nutrition 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000008239 natural water Substances 0.000 claims description 3
- 238000010926 purge Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 2
- 239000000385 dialysis solution Substances 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 36
- 239000000306 component Substances 0.000 description 319
- 229940088598 enzyme Drugs 0.000 description 126
- 230000000875 corresponding effect Effects 0.000 description 74
- 238000010586 diagram Methods 0.000 description 38
- 230000002829 reductive effect Effects 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 28
- 230000004060 metabolic process Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 238000004140 cleaning Methods 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 239000002699 waste material Substances 0.000 description 21
- 230000000717 retained effect Effects 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 230000002441 reversible effect Effects 0.000 description 17
- 230000001717 pathogenic effect Effects 0.000 description 16
- 150000003384 small molecules Chemical class 0.000 description 16
- 230000017531 blood circulation Effects 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 229920002521 macromolecule Polymers 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 108010015776 Glucose oxidase Proteins 0.000 description 9
- 239000004366 Glucose oxidase Substances 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 229940116332 glucose oxidase Drugs 0.000 description 9
- 235000019420 glucose oxidase Nutrition 0.000 description 9
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002616 plasmapheresis Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000000835 fiber Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000008105 immune reaction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000002572 peristaltic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 238000012958 reprocessing Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 238000000909 electrodialysis Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005373 pervaporation Methods 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108010068701 Pegloticase Proteins 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 208000026723 Urinary tract disease Diseases 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- -1 antibodies Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000009991 scouring Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 238000004065 wastewater treatment Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000010573 double replacement reaction Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008238 pharmaceutical water Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/027—Nanofiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3624—Level detectors; Level control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3626—Gas bubble detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/025—Reverse osmosis; Hyperfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nanotechnology (AREA)
- Emergency Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
一种流体处理方法及循环处理设备、系统，及医疗设备；其中，通过令流体在管路中流动以形成循环，循环中包括处理单元以对流体进行处理以选择性改变流体中的分子或分子组合的结构或浓度，由处理单元实现的处理过程可避免有益成分损失；通过至少一个循环实现对流体的处理，在任一循环中，令进入循环的待处理流体与离开循环的流体流速相等以保持循环中流体总量动态平衡以维持循环的可持续性，因此流体处理方法的持续时间可基于预设处理目标确定。
Description
PCT国内申请，说明书已公开。
Claims (83)
- PCT国内申请，权利要求书已公开。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310687443.1A CN116672533A (zh) | 2020-08-19 | 2020-08-27 | 医疗设备 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010837981 | 2020-08-19 | ||
| CN2020108379810 | 2020-08-19 | ||
| PCT/CN2020/111885 WO2022036739A1 (zh) | 2020-08-19 | 2020-08-27 | 流体处理方法及循环处理设备、系统 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310687443.1A Division CN116672533A (zh) | 2020-08-19 | 2020-08-27 | 医疗设备 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115461100A true CN115461100A (zh) | 2022-12-09 |
| CN115461100B CN115461100B (zh) | 2023-07-04 |
Family
ID=80322489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080100237.0A Active CN115461100B (zh) | 2020-08-19 | 2020-08-27 | 流体处理方法及循环处理设备、系统 |
| CN202310687443.1A Pending CN116672533A (zh) | 2020-08-19 | 2020-08-27 | 医疗设备 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310687443.1A Pending CN116672533A (zh) | 2020-08-19 | 2020-08-27 | 医疗设备 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12011691B2 (zh) |
| EP (1) | EP4183433A1 (zh) |
| CN (2) | CN115461100B (zh) |
| WO (1) | WO2022036739A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118159312A (zh) * | 2022-12-09 | 2024-06-07 | 上海心光生物医药有限责任公司 | 透析液再生循环系统及透析设备 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115074409B (zh) * | 2022-08-18 | 2022-12-06 | 意润健康产业（广州）有限公司 | 一种基于有机动植物原材料的小分子活性肽分离纯化系统 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028198A1 (en) * | 1995-03-13 | 1996-09-19 | Ao Forschungsinstitut Davos | An extracorporeal blood treatment apparatus and method for removal of free circulating infectious agents |
| CN101500701A (zh) * | 2006-08-16 | 2009-08-05 | 新加坡科技研究局 | 循环反应器 |
| CN102378636A (zh) * | 2009-03-31 | 2012-03-14 | 弗雷森纽斯医疗护理德国有限责任公司 | 用于确定和调节流体循环中至少一种溶解物质的浓度的装置和方法 |
| US20130102948A1 (en) * | 2010-04-19 | 2013-04-25 | Ilan K. Reich | Portable blood filtration devices, systems, and methods |
| CN103732271A (zh) * | 2011-04-12 | 2014-04-16 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
| WO2020004602A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社ジェイ・エム・エス | 透析装置及び補液制御方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5226076B2 (zh) | 1972-10-06 | 1977-07-12 | ||
| US4013564A (en) | 1975-03-17 | 1977-03-22 | Takeda Chemical Industries, Ltd. | Multipurpose metabolic assist system |
| DE3223051C2 (de) | 1982-06-21 | 1984-09-13 | Fresenius AG, 6380 Bad Homburg | Dialysevorrichtung mit geregelter Dialysierlösung |
| US5232696A (en) * | 1987-09-25 | 1993-08-03 | Massachusetts Institute Of Technology | Reduction of low density lipoproteins in biological fluids |
| US4955857A (en) | 1988-07-18 | 1990-09-11 | Shettigar Udipi R | Multi-enzyme bioreactor therapy for cancer |
| DE10324668A1 (de) * | 2003-05-30 | 2004-12-23 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur extrakorporalen Bestrahlung einer Bilirubin enthaltenden Flüssigkeit und Verfahren hierfür |
| CN100451031C (zh) | 2003-09-05 | 2009-01-14 | 东丽株式会社 | 生物体成分组成改变了的溶液的调制方法 |
| CA2553234C (en) | 2004-01-21 | 2012-07-24 | Toray Industries, Inc. | Fractionator and method of fractionation |
| CN103263704B (zh) | 2013-05-09 | 2015-10-28 | 浙江大学 | 配备储浆袋的血浆置换吸附滤过净化系统 |
| CN105408467A (zh) | 2013-07-23 | 2016-03-16 | 株式会社钟化 | 细胞浓缩液的制造方法以及细胞悬浊液处理系统 |
| EP2862584B1 (en) * | 2013-10-21 | 2019-03-20 | ICinnovation BV | Electrosorption and decomposition device for the purification of blood and other fluids |
| CN104225698B (zh) * | 2014-09-03 | 2016-04-13 | 西安交通大学 | 一种肝细胞微球循环生物人工肝支持系统 |
| CN106039448B (zh) * | 2016-07-01 | 2019-03-08 | 翁炳焕 | Aids细胞吸附治疗仪 |
-
2020
- 2020-08-27 CN CN202080100237.0A patent/CN115461100B/zh active Active
- 2020-08-27 CN CN202310687443.1A patent/CN116672533A/zh active Pending
- 2020-08-27 WO PCT/CN2020/111885 patent/WO2022036739A1/zh unknown
- 2020-08-27 US US18/020,623 patent/US12011691B2/en active Active
- 2020-08-27 EP EP20949946.6A patent/EP4183433A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028198A1 (en) * | 1995-03-13 | 1996-09-19 | Ao Forschungsinstitut Davos | An extracorporeal blood treatment apparatus and method for removal of free circulating infectious agents |
| CN101500701A (zh) * | 2006-08-16 | 2009-08-05 | 新加坡科技研究局 | 循环反应器 |
| CN102378636A (zh) * | 2009-03-31 | 2012-03-14 | 弗雷森纽斯医疗护理德国有限责任公司 | 用于确定和调节流体循环中至少一种溶解物质的浓度的装置和方法 |
| US20130102948A1 (en) * | 2010-04-19 | 2013-04-25 | Ilan K. Reich | Portable blood filtration devices, systems, and methods |
| CN103732271A (zh) * | 2011-04-12 | 2014-04-16 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
| WO2020004602A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社ジェイ・エム・エス | 透析装置及び補液制御方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118159312A (zh) * | 2022-12-09 | 2024-06-07 | 上海心光生物医药有限责任公司 | 透析液再生循环系统及透析设备 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4183433A1 (en) | 2023-05-24 |
| WO2022036739A1 (zh) | 2022-02-24 |
| US20230321603A1 (en) | 2023-10-12 |
| US12011691B2 (en) | 2024-06-18 |
| CN116672533A (zh) | 2023-09-01 |
| CN115461100B (zh) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2800592B1 (en) | Multi-staged filtration system for blood fluid removal | |
| US5855782A (en) | Arrangement for removing substances from liquids, in particular blood | |
| EP0643614B1 (en) | A plasma filter sorbent system for removal of components from blood; improved mass transport system | |
| US20130102948A1 (en) | Portable blood filtration devices, systems, and methods | |
| EP2771045B1 (en) | Method for the reduction or elimination of one or more components from a blood product | |
| JP2001524839A (ja) | 選択的膜／吸着手法による自己血液の回収 | |
| CA2227550A1 (en) | Affinity membrane system and method of using same | |
| WO2005107928A9 (en) | Metabolic detoxification system and method | |
| EP2076297A2 (en) | Fluid-conserving cascade hemofiltration | |
| CN115461100B (zh) | 流体处理方法及循环处理设备、系统 | |
| JP2020523042A (ja) | 中空糸フィルタモジュールおよび高分子収着剤の組合せで構成される体外循環回路を用いて血液から毒素を除去する方法 | |
| EP3490696B1 (en) | Flow capture device for removing cells from blood | |
| CN115697430B (zh) | 流体处理方法及流体处理装置 | |
| US20240252731A1 (en) | A Secondary Plasma Device for Collection of Cell-free Nucleic Acids from Blood Plasma During Extracorporeal Blood Processing by Clinical Apheresis Machines | |
| JP2814399B2 (ja) | 全血処理用吸着器 | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| WO2024120144A1 (zh) | 透析液再生循环系统及透析设备 | |
| WO2015011290A1 (en) | Blood purification systems and devices with internally generated replacement fluid | |
| CN118159312A (zh) | 透析液再生循环系统及透析设备 | |
| Bronzino et al. | Therapeutic Apheresis and Blood Fractionation | |
| JPH11207150A (ja) | 生菌を用いた液体浄化器および液体浄化装置 | |
| JPS58173554A (ja) | 血液の浄化装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |